Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Trilogy Capital Inc.

Trilogy Capital Inc. cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 41,072 shares of the biopharmaceutical company’s stock after selling 235 shares during the quarter. Trilogy Capital Inc.’s holdings in Gilead Sciences were worth $3,444,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. CarsonAllaria Wealth Management Ltd. grew its holdings in Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 238 shares during the period. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter valued at $25,000. Palisade Asset Management LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth $29,000. Cedar Wealth Management LLC raised its position in shares of Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences during the second quarter valued at $33,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $86.72 on Monday. The firm has a fifty day moving average price of $81.06 and a two-hundred day moving average price of $72.82. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The company has a market cap of $108.04 billion, a PE ratio of 240.89, a price-to-earnings-growth ratio of 2.98 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Analysts expect that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.55%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Analysts Set New Price Targets

A number of equities analysts recently commented on GILD shares. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Sanford C. Bernstein initiated coverage on Gilead Sciences in a research report on Thursday. They set an “outperform” rating and a $105.00 price target on the stock. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $74.00 to $96.00 in a research note on Monday. BMO Capital Markets increased their price target on shares of Gilead Sciences from $85.00 to $94.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research report on Monday, July 8th. Ten research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $86.85.

Insider Activity

In related news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,847 shares of company stock worth $3,033,340. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.